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Abstract
Background:  To evaluate the relationship between Aberrant Crypt Foci (ACF) and
tumorigenesis, we observed the sequential development from ACF to tumor in the colon of
azoxymethane-exposed wistar rats.
Methods:  Sixty wistar rats were sacrificed at different time points after exposure to
azoxymethane and the colons were stained with methylene blue for stereomicroscopic analysis.
Results: We found two types of early lesions: classic ACF and dark ACF. Dark ACF were
characterized by dark blue staining, mildly enlarged or small compressed crypts that are not
elevated from the surrounding epithelium. Large dark ACF and nascent tumors displayed the same
surface morphology. Furthermore, dark ACF grew significantly faster than classic ACF and showed
dysplasia without hyperplasia. In contrast, classic ACF showed hyperplasia without dysplasia. Dark
ACF has significant higher expression rate of β-catenin (100%) and MMP-7 (81.82%) compared with
the expression of β-catenin and MMP-7 in classic ACF (4.84% and 7.87%, respectively).
Conclusion: Our data indicated that dark ACF is closely related to tumorigenesis while classic
ACF is not. Furthermore, Wnt signal pathway was activated during the early period of dark ACF.
Background
Aberrant crypt foci (ACF) were first described by Bird and
Good. The lesion of ACF is composed of the enlarged
crypts that are slightly elevated above the surrounding
mucosa and the densely stained crypts with methylene
blue [1]. ACF are considered as putative preneoplastic
lesions of the colon in both humans and experimental
animals [2,3].
Although ACF may share some morphologic, genetic, and
biochemical features with colonic tumors [4-7], conflict-
ing evidence has also been reported. For example, muta-
tions in the K-ras gene are relatively common in human
ACF, but are only detected at a relatively late stage of colon
cancer [8-11]. In rat models, although hundreds of ACF
are induced per animal by azoxymethane (AOM), and K-
ras mutations are frequently observed in those ACF, only
a few colon tumors are observed per animal [12-14]. In
azoxymethane/dimethylhydrazine-treated rats and in
patients with sporadic colorectal cancer, the number of
tumors is minuscule compared with the large number of
ACF [15], demonstrating that only a very small fraction of
the ACF in theory has the potential to progress to the stage
of a tumor. Therefore, there is a strong need to investigate
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the role of ACF in colon carcinogenesis. Alexander et al.
[18] observed a type of small flat dysplastic lesions that
was denoted as ACFMin in Min/+ mice, an Apc/familial
adenomatous polyposis model. ACFMin exhibited dys-
plastic crypts similar to those found in adenomas and
only those ACFMin showed a continuous development
from the monocryptal stage to adenoma with rapid mul-
tiplication of crypts and altered expression of β-catenin. In
contrast, the classic elevated ACF are hyperplastic, slow-
growing, and show normal expression of β-catenin sug-
gesting they are not directly associated with tumorigenesis
[16-18].
The Wnt pathway controls the cell fate during the embry-
onic development. It not only drives tumorigenesis but
also is required at different stages during the gut develop-
ment. Activated Wnt signal pathway precludes the post-
translational down-regulation of β-catenin, which
consequently accumulates in the cytoplasm and translo-
cates into the nucleus where it complexes with the tran-
scription factor Tcf-4 and activates specific target genes
(such as c-MYC, cyclin D1 and MMP-7, etc.) [19].
In this study we evaluated the relationship between ACF
and tumorigenesis by observing the sequential develop-
ment from ACF to tumor in AOM-treated rats. In addition,




Sixty male SPF Wistar rats (8 to 9 weeks old; ~180 g
weight) were provided by Nanfang Medical University
animal center. the animal use is approved by the Animal
Care and Use committee (approval number: 2002-009
2004B023 2004A068)and all the protocols are in agree-
ment to the requirement of the committee. AOM (Sigma,
St. Louis, MO, USA) was dissolved in 0.9% NaCl immedi-
ately before use and adjusted to pH 6.5–7.0. Rats were
injected subcutaneously with azoxymethane (15 mg/kg
bw/injection) once a week for 2 weeks. Animals were sac-
rificed sequentially from weeks 8 to 25 after the last injec-
tion of azoxymethane. The colons stained with methylene
blue were transilluminated in the stereomicroscope, and
the colonic lesions were characterized and scored based
on the morphology of the tissues. The lesions were dis-
sected and characterized by histopathological (for experi-
mental details, see Table 1) and immunohistochemical
analysis.
Scoring of classic ACF, dark ACF, and tumors
The colons were removed, rinsed in ice-cold PBS, slit open
longitudinally, and fixed flat between two wet (PBS) filter
papers for 48 hours in 10% neutral buffered formalin fol-
lowed by 10 seconds staining with 0.2% methylene blue
(Chemical Ltd, Guangzhou, China) dissolved in the same
formalin solution. Deeply stained crypts were examined
by transillumination in stereomicroscopy after staining.
Classic ACF were characterized by their obvious enlarged
crypts, slight elevation above the surrounding mucosa
thickened layer of epithelial cells, increased pericryptal
space, and their light blue staining. Dark ACF were char-
acterized by having dark blue staining, moderate enlarged
or small crypts that are elevated from the surrounding epi-
thelium and mild enlarged or small compressed crypts
that are not elevated from the surrounding epithelium.
Thus, darker blue staining and compressed pit pattern
were used as the criteria for identification of dark ACF. The
size of the lesions was scored by crypt multiplicity (AC/
lesion). The crypt multiplicity of lesions was determined
by transforming the diameter (mm) scored with an eye-
piece to the crypt multiplicity by using the following
empirical formula: c = 20 × d2. The lesions containing >32
aberrant crypts were defined as tumors.
Histopathological analysis
Areas with mucosal lesions identified by examining the
surface of the whole colon preparations in the stereomi-
croscopy were dissected and embedded in paraffin wax.
After embedding, the tissue samples were sectioned in
parallel with the mucosal surface. If the lesions have more
than 32 aberrant crypts, then the tissues samples were sec-
tioned in vertical with the mucosal surface. All sections
were stained with H & E. Blind examination of the lesions
from different levels of the crypts was performed by two
pathologists.
Table 1: Histopathologic examination of classic ACF, dark ACF, and tumor
Hyperplasia without dysplasia Mild dysplasia Morderate dysplasia Severe dysplasia
W8-14 W16-21 W22-25 W8-14 W16-21 W22-25 W8-14 W16-21 W22-25
Classic ACF 165 0 0 0 0 0 0 0 0 0
D a r k  A C F 0 10 0 27 2 04 6
t u m o r 0 0 000 030 16
Note: No. rats (n) used at each time point after AOM treatment: Wk8, 10, 12, 14, 16, 18, 20, 21,22, 23, 24, 25 = 5, respectively.Journal of Experimental & Clinical Cancer Research 2008, 27:26 http://www.jeccr.com/content/27/1/26
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Histopathological classification was based on the follow-
ing criteria. Hyperplasia with no dysplasia was character-
ized as having slightly dilated crypts with normal
epithelium. Mild dysplasia was characterized as having
elongated, crowded and pseudostratified nuclei with well
preserved polarity and normal or slightly reduced number
of goblet cells. Moderate dysplasia was characterized as
having elongated, more crowded and pseudostratified
nuclei with well preserved polarity and more reduced
number of goblet cells than in mild dysplasia. Severe dys-
plasia was characterized as having enlarged, round or
ovoid nuclei with prominent nucleoli. The polarity of the
nuclear in severe dysplasia is partially lost and the number
of the goblet cells is significantly reduced or completely
lost.
Immunohistochemical analysis
Paraffin-embedded formalin-fixed sections were pre-
pared, deparaffinized, and rehydrated in xylene, graded
alcohol, and water. Demasking was performed in micro-
wave oven for 12 minutes in Tris-EDTA solution. To deter-
mine the expression of β-catenin, sections were stained
with monoclonal anti-β-catenin antibody (Wuhan Boster
Ltd, Cat. No. BA0426, Wuhan, China) at the dilution of
1:200 and counterstained with hematoxylin using a SP
kit. To determine the expression of MMP-7, sections were
stained with monoclonal anti-MMP-7 antibody (Wuhan
Boster Ltd, Cat. No. BA2110) at the dilution of 1:200 and
counterstained with hematoxylin using a SP kit. β-catenin
expression was evaluated separately for the cell mem-
brane, cytoplasmic and nuclear compartments. If more
than 70% of the membranes in the lesion cells were posi-
tively stained by the antibody, the membranous expres-
sion of β-catenin in the lesions was judged to be normal.
If less than 70% of membranes in the lesion cells were
positively stained, the membranous expression of β-cat-
enin was judged to be reduced. On the other hand, if more
than 10% of the cells were positive for the β-catenin stain-
ing in cytoplasm/nucleus, it was considered as cytoplasm/
nucleus  β-catenin expression because normal colonic
mucosal cell cytoplasm/nucleus shows negative β-catenin
expression. Thus, if more than 10% of the lesion cells
showed elevated β-catenin labeling in the cytoplasm and/
or distinct nuclear staining, the lesion was recorded as
having cytoplasmic overexpression and/or nuclear accu-
mulation of β-catenin. Reduced cell membrane expres-
sion or cytoplasmic overexpression/nuclear accumulation
are recognized as altered expression. Cytoplasmic overex-
pression/nuclear accumulation are also called ectopic
expression. For MMP-7, the criterion for positive expres-
sion was the presence of prominent cytoplasmic staining.
Statistical analysis
X2 test was used to calculate the statistical difference of
proportions between groups. Student's t test was used to
compare two groups and one-way ANOVA was used to
compare ranks between multiple groups.
Results
Stereomicroscopy and histopathological analysis revealed 
two types of ACF:classic ACF and dark ACF
Examination of the surface in the colon with stereomicro-
scopy revealed two types of ACF: classic ACF and dark ACF
(Fig. 1A). Dark ACF were characterized by their darker
blue staining than classic ACF. Furthermore, dark ACF
have mild enlarged or small compact crypts that are not
elevated from the surrounding epithelium. Histopatho-
logical examination showed that the lesions were classi-
fied into four categories: (1) hyperplasia without
dysplasia; (2) mild dysplasia; (3) moderate dysplasia; and
(4) severe dysplasia. All the classic ACF (165 cases)
showed hyperplasia without dysplasia (Fig. 1B). The aver-
age crypt multiplicity for classic ACF slightly increased
from 3.93 crypt/lesion at weeks 8~14 to 4.52 crypts/lesion
at week 22~25 (F = 3.17, P = 0.278) (Table 2). In contrast,
all the 22 dark ACF cases showed dysplasia with different
degree (Fig. 1C) and the crypt with moderate or severe
dysplasia accounted for 95.4% (21/22) of the cases. The
average focal crypt multiplicity of dark ACF increased sig-
nificantly between different categories (F = 15.4, P =
0.000), In addition, crypt multiplicity of dark ACF
increased significantly faster than those of classic ACF.
Dark ACF is phenotypically similar to tumor
Nascent tumors exhibited characteristic of dark blue stain-
ing and contained branched or gyrus-like pit pattern of
compressed crypts (Fig. 1D). In addition, nascent tumors
displayed the same surface morphology as dark ACF. All
the tumors showed moderate or severe dysplasia (10 of
10). There was no significant difference between the pro-
portion of morderate/severe dysplasia in dark ACF
(95.4%) and that in tumors (100%). The rapid increase of
crypt multiplicity in dark ACF is similar to the characteris-
tic of tumors.
Expression of β-catenin in classic ACF, dark ACF and 
tumors
The immnoreactivity of β-catenin in the classic ACF, dark
ACF and tumors is summarized in Table 3. Expression of
β-catenin is normal in most of the classic ACF (157 of
165, Fig. 2A). Four of the classic ACF showed reduced
expression in cell membrane and the other four classic
ACF showed cytoplasmic expression of β-catenin. In con-
trast, 72.72% (16/22) of dark ACF showed cytoplasmic
overexpression or nuclear accumulation (Fig. 2C). All the
ten tumor cases showed cytoplasmic overexpression or
nuclear accumulation of β-catenin. Interestingly, the
expression pattern of β-catenin for dark ACF or tumors
was mainly characterized by reduced expression in mem-
brane during the early period (week 8~14) and then tran-Journal of Experimental & Clinical Cancer Research 2008, 27:26 http://www.jeccr.com/content/27/1/26
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sited to nuclear accumulation during the later period
(week 22~25) (Table 4).
Expression of mmp-7 in classic ACF, dark ACF and tumors
The immnoreactivity of mmp-7 in the classic ACF, dark
ACF and tumors is summarized in Table 3. The expression
rate of mmp-7 in dark ACF (Fig. 2D) was 81.82% (18/22),
which was significantly higher than that in classic ACF
(7.87%, 13/165) (Fig. 2B). All the tumor cases exhibited
cytoplasmic overexpression of mmp-7. Furthermore,
there was no significant difference between expression of
mmp-7 in dark ACF and tumors.
Discussion
By examining the sequential development of early lesions
in the colon of Wistar rats 8 to 25 weeks after AOM treat-
ment, we identified two types of lesions: classic ACF and
dark ACF. Dark ACF were characterized by their darker
blue staining than the classic ACF. In addition, dark ACF
has mildly enlarged or small crypts that are not elevated
Morphological observations of classic ACF, dark ACF and tumors Figure 1
Morphological observations of classic ACF, dark ACF and tumors. Morphological observations of classic ACF, dark 
ACF and tumors. Lesions were stained with methylene blue and examined with the stereomicroscope (A, D, ×20); black 
arrowheads represent classic ACF and white arrowheads represent dark ACF. Histological observation (B, C, E) are derived 
from the same lesions as seen in A and D. Classic ACF showed hyperplasia without dysplasia (B, ×100); dark ACF showed 
moderate dysplasia (C, ×100); small tumor showed severe dysplasia (E, ×100).
Table 2: Crypt multiplicity of classic ACF, dark ACF, and tumors (mean ± SD)
crypt multiplicity (No. of crypts/lesion/group)
W8-14 W16-21 W22-25 F P
Classic ACF 3.93 ± 0.89 4.73 ± 1.12 4.52 ± 1.03 3.17 0.278
Dark ACF 6.00 ± 3.00 10.73 ± 4.03 18.38 ± 3.54 15.40 0.000
t 3.330 9.883 11.204
P 0.002 0.000 0.000Journal of Experimental & Clinical Cancer Research 2008, 27:26 http://www.jeccr.com/content/27/1/26
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from the surrounding epithelium. The crypts of dark ACF
is compact and similar to a compressed luminal opening.
Dark ACF shares similarities with tumors with regard to
the surface morphology of the colon, higher crypt multi-
plicity, pathologic classification and expression pattern of
β-catenin and mmp-7. However, classic ACF are different
to tumors. These results may explain why only a few colon
tumors are observed although hundreds of ACF are
induced per animal. Activation of β-catenin, a core pro-
tein in Wnt signal transduction pathway in nucleus, corre-
lates with the tumorigenesis and abnormal accumulation
of β-catenin plays an important role in the development
of tumors [20-22]. One of the studies found that β-catenin
is less expressed in the membrane of ACF, but more
expressed in cytoplasm and nucleus when ACF variation
increases [23]. Our study showed that the ectopic expres-
sion ratio of β-catenin was 72.7% in dark ACF, which had
no significant difference compared with that in tumors. In
Immunohistochemical analyses for the expression of β-catenin and mmp-7 in classic ACF, dark ACF and histological sections of  lesions Figure 2
Immunohistochemical analyses for the expression of β-catenin and mmp-7 in classic ACF, dark ACF and histo-
logical sections of lesions. Immunohistochemical analyses for the expression of β-catenin and mmp-7 in classic ACF, dark 
ACF and histological sections of lesions. The expression of β-catenin (A) and mmp-7 (B) is not altered in classic ACF. The 
expression of β-catenin (C) and mmp-7 (D) is altered in dark ACF. Magnification: ×100.Journal of Experimental & Clinical Cancer Research 2008, 27:26 http://www.jeccr.com/content/27/1/26
Page 6 of 7
(page number not for citation purposes)
addition, expression pattern of β-catenin transited from
reduced cell membrane expression in the early period to
nuclear accumulation in the later period. Simultaneously,
activation of oncogene encoding β-catenin could stimu-
late the downstream target, MMP-7, to suppress tumor
cell apoptosis and degradation of basic membrane. Duan
et al. [24] found that expression of β-catenin in cytoplasm
and nucleus directly correlated with the expression of
MMP-7 protein, suggesting that abnormal expression of β-
catenin could initiate Wnt signal transduction pathway
leading to the expression of MMP-7. Our study found that
β-catenin ectopic expression ratio was positively corre-
lated with the MMP-7 positive ratio, and meanwhile,
there was no statistical difference between the expression
of MMP-7 in dark ACF and that in tumors. These results
suggested that increased β-catenin accumulation in dark
ACF activated the Wnt pathway leading to the loss of cell
adhesion and separation. Loss of cell adhesion and sepa-
ration resulted in more contact between cells and high
expression of MMP-7, leading to further degradation of
the outer membrane and unlimited cell growth. Dark ACF
obtained the ability to grow invasively and was converted
to colon cancer. We found that β-catenin and MMP-7
expression was not changed in classic ACF, which sug-
gested that oncogene activation and expression does not
exist in classic ACF. Therefore, the chance of conversion
from classic ACF to tumors is relatively small.
Conclusion
In summary, we identified two types of ACF: dark ACF
and classic ACF. Dark ACF is similar to tumor with regard
to its morphological and pathological changes, the
increased number of crypts and the expression oncogenes.
However, all these features identified in dark ACF and
tumors were not observed in classic ACF. These results
suggested that not all ACF are early indications of colon
cancers and only a specific type of ACF (dark ACF) may be
used for diagnosis and evaluation of anticancer abilities of
chemicals and food additives. Furthermore, our results
also showed that the key proteins in the Wnt signal trans-
duction pathway were abnormally expressed suggesting
that the activation of Wnt pathway exists in the stage of
ACF during the cancer development. Future studies will be
focused on the pathological changes and activation of sig-
nal transduction pathways during earlier stages of ACF.
Abbreviations
ACF: aberrant crypt foci; AOM: azoxymethane.
Table 3: Immunohistochemical analysis for the expression of β-catenin, mmp-7 in classic ACF, dark ACF and tumor
β-catenin mmp-7
No. of normal 
samples/total No. 
of samples








No. of samples with 
accumulated 
expression in 
nucleus/total No. of 
samples








Classic ACF 157/165 4/165 4/165 0/165 13/165 152/165
Dark ACF 0/22 6/22 8/22 8/22 18/22 4/22
Tumor 0/10 0/10 3/10 7/10 10/10 0/10
Note: The rate of ectopic expression of β-catenin in classic ACF is significantly lower than that in tumors (P = 0.0023). The rate of mmp-7 
expression in classic ACF is significantly lower than that in tumors (P = 0.000). The rate of β-catenin ectopic expression and positive expression of 
mmp-7 in dark ACF is not significantly different with those in tumor (P = 0.143 and P = 0.283, respectively). The rate of ectopic expression of β-
catenin in dark ACF is significantly higher than that in classic ACF (P = 0.000). The rate of mmp-7 expression in dark ACF is significantly higher than 
that in classic ACF (P = 0.000).
Table 4: Expression of β-catenin in dark ACF at different time point
β-catenin expression
No. of samples with reduced expression in 
membrane/total No. of samples
No. of samples with overexpression in 
cytoplasm/total No. of samples
No. of samples with accumulated expression 
in nucleus/total No. of samples
Wk8-14 3/3 0/3 0/3
Wk16-21 3/11 5/11 3/11
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